ARA-290
ARA-290, also called cibinetide, is an erythropoietin-derived peptide investigated in tissue-protection research. A small clinical pilot examined neuropathy symptoms in people with sarcoidosis.
Research topics
Read the studies →
EXPLORE THE BIOLOGY
Content updated · how dates work
Tendon, wound, and connective-tissue research.
This topic groups related research questions. Shared biology does not make different peptides interchangeable, or establish a clinical benefit. Compare each paper’s population, preparation, and measured outcome.
Each peptide is sorted by the strongest kind of human study among its profile’s selected studies, and the row shows what that study found and who was studied. A higher tier means stronger evidence exists, not that the peptide works for tissue repair: the best trial may be small, negative or about a different condition. No doses.
| Peptide | Strongest human evidence in our sources | FDA | Human safety data |
|---|---|---|---|
| Randomized human trials (5)At least one randomized or placebo-controlled trial, which may be small, negative or about another condition. | |||
| ARA-290 | Sarcoidosis-associated small-fiber neuropathy pilot (2012) · Human randomized pilot trial The small-fiber-neuropathy symptom score improved more with ARA-290. Brief Pain Inventory pain and fatigue measures improved similarly in both groups; depression did not change. Limitation: A small, short pilot cannot establish durable recovery. A positive neuropathy score should not be presented as a significant benefit on every measured pain or fatigue outcome. Studied: 22 people with sarcoidosis and small-fiber neuropathy. | Not approved | Trials only |
| GHK-Cu | Laser-resurfacing skin study (2006) · Small human randomized trial (topical) No significant difference in redness resolution, wrinkles or overall skin quality on objective measures; patients using GHK-Cu reported higher satisfaction on a questionnaire. Limitation: Thirteen people, a cosmetic skin product and a mostly negative objective result. It says nothing about injected GHK-Cu, which is what FDA flagged. Studied: 13 adults who completed the study after CO2 laser resurfacing around the mouth. | Not approved | Very limited |
| LL-37 | LL-37 · first topical ulcer trial (2014) · Human randomized trial The lowest concentration had a significantly higher healing-rate constant than placebo (P=0.003); the middle comparison did not reach significance (P=0.088). The highest concentration showed no healing difference. Limitation: Small sample and short follow-up limit confidence. The later 148-person trial did not improve healing overall. These topical findings do not establish systemic antimicrobial efficacy or safe injectable use. Studied: 34 people with hard-to-heal venous leg ulcers. | Not approved | Trials only |
| Thymosin beta-4 | RGN-259 dry-eye phase 2 study (2015) · Human randomized trial Neither primary endpoint—ocular discomfort nor inferior corneal staining at day 29—showed a statistically significant treatment benefit. Some secondary outcomes favored treatment. Limitation: Secondary findings should be interpreted alongside failure of the primary endpoints. The ophthalmic route and dry-eye population do not establish safety or efficacy of systemic use. Studied: 72 people with moderate to severe dry eye. | Not approved | Trials only |
| TP-508 | TP-508 (Chrysalin) applied to diabetic foot ulcers (2007) · Human randomized phase 1/2 trial Among participants treated as planned (per protocol), complete healing was more than twice as common with TP-508 as with placebo, the average closure rate was about 80% higher, and median time to full closure was about 40% shorter. Heel ulcers showed the largest difference: 6 of 7 healed completely with TP-508 versus 0 of 5 with placebo. Wound reactions and adverse events were similar between groups. Limitation: A small pilot trial whose reported benefits come from the per-protocol group, not necessarily everyone randomized, and the heel-ulcer result rests on 12 ulcers. No larger diabetic foot ulcer trial was found, and the later phase 3 fracture trial missed its main clinical goal. Studied: 60 adults with diabetic foot ulcers receiving standardized wound care and off-loading. | Not approved | Trials only |
| Small or uncontrolled human studies (2)Human reports without randomization, such as pilots, case series or open-label studies. | |||
| BPC-157 | BPC-157 · knee-pain chart review (2021) · Retrospective human chart review The authors reported that 14 of 16 patients (87.5%) described significant knee-pain relief, including 11 of 12 who received BPC-157 alone. Limitation: The knee problems varied, follow-up was inconsistent, and no imaging or function measures were used. The study did not systematically record side effects, so it says little about safety. Controlled trials would be needed to support a benefit. Studied: 16 patients at one U.S. primary-care hormone clinic, reached by phone 6–12 months after a knee injection; 12 received BPC-157 alone and 4… | Not approved | Very limited |
| PEG-MGF | Natural MGF after exercise · young vs older men (2003) · Human observational study MGF messenger RNA rose significantly in the young men but not in the older men. Limitation: Measures the body's own gene activity, not the effect of taking a synthetic peptide. Small groups. Studied: 8 young men (25–36) and 7 older men (70–82). | Not approved | None |
| Animal and lab studies only (4)No human study in our sources. | |||
| B7-33 | See the profile for the animal and lab research. | Not approved | None |
| MGF | See the profile for the animal and lab research. | Not approved | None |
| PTD-DBM | See the profile for the animal and lab research. | Not approved | None |
| TB-500 | See the profile for the animal and lab research. | Not approved | None |
Selected studies, not a systematic review. Approval belongs to a specific product and use. Side-by-side comparisons: BPC-157 vs TB-500 · Thymosin alpha-1 vs Thymosin beta-4 · GHK-Cu vs AHK-Cu (all comparisons).
ARA-290, also called cibinetide, is an erythropoietin-derived peptide investigated in tissue-protection research. A small clinical pilot examined neuropathy symptoms in people with sarcoidosis.
Research topics
Read the studies →B7-33 is a short, lab-designed peptide built from part of relaxin-2, a natural hormone best known for its role in pregnancy. It was designed to keep relaxin's anti-scarring and blood-vessel effects in a smaller molecule. Its evidence comes from animal and cell studies, not people.
Research topics
Read the studies →BPC-157 is a 15-amino-acid research peptide. Selected animal injury studies and a two-person human safety pilot explore different questions; neither establishes treatment benefit for injured patients.
Research topics
Read the studies →GHK-Cu combines a short peptide with copper. It is discussed in topical skin care and tissue-remodeling research, which should be separated from injection claims.
Research topics
Read the studies →LL-37 is the only human cathelicidin: a 37-amino-acid host-defense peptide made by white blood cells and by the lining of the skin, gut and airways. As a treatment it has been tested only on the skin of chronic ulcers. A small 2014 trial was positive, but a 148-patient phase 2b trial missed its main healing goal.
Research topics
Read the studies →MGF can refer to an IGF-1 splice-product context or a synthetic terminal E-peptide. A primary replication study found no apparent effect of the tested MGF peptides on muscle-cell proliferation or differentiation.
Research topics
Read the studies →PEG-MGF is a synthetic piece of mechano growth factor, an IGF-1 splice variant that loaded muscle makes, with polyethylene glycol attached to make it last longer. The muscle-growth claim comes from cell studies that a two-company replication could not reproduce, and no published study has tested PEG-MGF itself in cells, animals or people.
Research topics
Read the studies →PTD-DBM is an experimental motif peptide investigated in Wnt-associated hair-follicle biology. The featured work included human tissue and cells alongside mouse experiments, rather than a controlled human hair-regrowth trial.
Research topics
Read the studies →TB-500 is associated with a short thymosin beta-4 fragment. Much of the biology cited in marketing instead concerns the full-length parent peptide.
Research topics
Read the studies →Thymosin beta-4 is a full-length 43-residue peptide studied in tissue biology. The selected human study tested an ophthalmic preparation for dry eye, with negative primary endpoints.
Research topics
Read the studies →TP-508, also called rusalatide acetate or Chrysalin, is a lab-made 23-amino-acid peptide copied from part of thrombin, a protein involved in blood clotting and tissue repair. It was tested in people for diabetic foot ulcers and wrist fractures. A large phase 3 fracture trial missed its main goal, no later human trials are registered, and it is not approved.
Research topics
Read the studies →See something wrong on this page? Report a mistake · Corrections